Difference in survival between COPD patients with an impaired immune reaction versus an adequate immune reaction to seasonal influenza vaccination: The COMIC study - 11/05/22
, E. Citgez c, M. Zuur-Telgen c, H.A.M. Kerstjens d, G. Rijkers e, f, P.D.L.P.M. VanderValk c, J. van der Palen a, gAbstract |
Aim |
To study the hypothesis that COPD patients who do not achieve seroprotective levels after influenza vaccination, are a less immune-competent group with a higher risk of morbidity and mortality.
Methods |
578 patients included in the COMIC cohort had pre- and post-vaccination stable state blood samples in which influenza-vaccine specific antibodies were measured. Post-vaccination titers of ≥40 were considered protective and indicative of being immuno-competent. Primary outcome was all-cause mortality. Morbidity was defined as time till first severe acute exacerbation in COPD (severe AECOPD) and time till first community acquired pneumonia (CAP).
Results |
42% of the patients achieved seroprotective levels to both H1N1 and H3N2 after vaccination. Seroprotective levels to H3N2 were markedly higher (96%) than to H1N1(43%). Having seroprotective levels to both H1N1 and H3N2 was not associated with less morbidity (severe AECOPD HR 0.91 (95% 0.66–1.25; p = 0.564) (CAP HR 1.23 (95% 0.75–2.00; p = 0.412)) or lower mortality (HR 1.10(95% 0.87–1.38; p = 0.433)).
Conclusion |
In a large well-characterized COPD cohort only the minority of patients achieved seroprotective titers to H1N1 and H3N1 after the yearly influenza vaccination. While achieving seroprotection after vaccination can be considered a surrogate marker of being immunocompetent, this was not associated with lower morbidity and mortality. Whether this means that the immune status is not a relevant pheno/endotype in COPD patients for the course of their disease or that seroprotection is not an adequate (surrogate) marker to define the immune status in COPD needs to be further studied.
Il testo completo di questo articolo è disponibile in PDF.Highlights |
• | Only 42% of COPD patients achieved seroprotective titers to H1N1 and H3N1 after the yearly influenza vaccination. |
• | Seroprotective levels to H3N2 were markedly higher than to H1N1. |
• | Having seroprotective levels to both H1N1 and H3N2 was not associated with less morbidity or lower mortality. |
Keywords : Influenza vaccination, COPD, Survival, Mortality, Immune reaction, Hospitalization, Pneumonia
Mappa
Vol 197
Articolo 106851- giugno 2022 Ritorno al numero
Articolo precedente
- Changes in critical inhaler technique errors in inhaled COPD treatment – A one-year follow-up study in Sweden
- Johanna Sulku, Christer Janson, Håkan Melhus, Björn Ställberg, Kristina Bröms, Marieann Högman, Karin Lisspers, Andrei Malinovschi, Elisabet I. Nielsen
- Characteristics and outcomes of ambulatory patients with suspected COVID-19 at a respiratory referral center
- Vamsi P. Guntur, Brian D. Modena, Laurie A. Manka, Jared J. Eddy, Shu-Yi Liao, Nir M. Goldstein, Pearlanne Zelarney, Carrie A. Horn, Rebecca C. Keith, Barry J. Make, Irina Petrache, Michael E. Wechsler
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?